Overview

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

A single-center prospective exploratory single-arm neoadjuvant therapy study, based on a prospective cohort study, according to patients' blood and tumor samples before and after neoadjuvant treatment, WES, GEP gene expression profiling, TCR sequencing and ctDNA dynamic monitoring were used to explore the intratumoral immune consequences of PD-1 monoclonal antibody administration and identify potential Response biomarker.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborator:

AstraZeneca

Treatments:

Carboplatin
Durvalumab
Paclitaxel